BRCA1 in hormonal carcinogenesis: Basic and clinical research

Endocrine-Related Cancer

Volumn 12, Issue 3, 2005, Pages 533-548

  Rosen, E M ^a   Fan, S ^a   Isaacs, C ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ANDROGEN RECEPTOR; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN D1; DIMETHYLBENZ[A]ANTHRACENE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GENISTEIN; HORMONE RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR 2; ORGANOCHLORINE DERIVATIVE; PROTEIN C MYB; PROTEIN P53; TAMOXIFEN;

AGE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST FEEDING; CANCER RESEARCH; CANCER RISK; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CHROMOSOME 17Q; CLINICAL RESEARCH; CLINICAL TRIAL; DNA DAMAGE; ENDOMETRIUM CANCER; GENE MUTATION; HORMONAL CARCINOGENESIS; HORMONE SUBSTITUTION; HUMAN; MENARCHE; ONCOGENE; ORAL CONTRACEPTION; OVARIECTOMY; OVARY CANCER; PARITY; PREGNANCY; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; UTERUS CANCER;

BREAST NEOPLASMS; CARRIER STATE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, BRCA1; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 26944444679     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00972     Document Type: Review

References (130)

1. Adern C, Soderberg CL, Hafner K, Reynolds C, Slezak JM, Sinclair CS, Sellers TA, Schaid DJ, Couch F, Hartmann LC & Jenkins RB 2004 ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes and Cancer 41 1-11.
2. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML & Lanzino M 2002 Breast cancer: from estrogen to androgen receptor. Molecular and Cellular Endocrinology 193 121-128.
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG & Easton DF 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics 72 1117-1130.
4. Arbeit JM, Howley PM & Hanahan D 2003 Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. PNAS 93 2930-2935.
5. Archey WB, McEachern KA, Robson M, Offit K, Vaziri SA, Casey G, Borg A & Arrick BA 2002 Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogens 21 7034-7041.
6. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL & Venter DJ 1999 Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Research 59 2011-2017.
7. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J & Nilsson S 1998 Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Molecular Pharmacology 54 105-112.
8. Bennett LM, McAllister KA, Malphurs J, Ward T, Collins NK, Seely JC, Gowen LC, Koller BH, Davis BJ & Wiseman RW 2000 Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Research 60 3461-3469.
9. Berns EM, Dirkzwager-Kiel MJ, Kuenen-Boumeester V, Timmermans M, Verhoog LC, van den Ouweland AM, Meijer-Heijboer H, Klijn JG & van der Kwast TH 2003 Androgen pathway dysregulation in BRCA1-mutated breast tumors. Breast Cancer Research and Treatment 79 121-127.
10. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF & Koonin EV 1997 A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. Federation of American Societies for Experimental Biology Journal 11 68-76.
11. Bradlow HL, Michnovich J, Telang NT & Osborne MP 1991 Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12 1571-1574.
12. Breast Cancer Linkage Consortium 1997 Pathology of familial breast cancer differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349 1505-1510.
13. Brodie SG, Xu X, Qiao W, Li WM, Cao L & Deng CX 2001 Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20 17514-17523.
14. Brzovic PS, Rajagopal P, Hoyt DW, King MC & Klevit RE 2001 Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nature Structural Biology 8 833-837.
15. Cabanes A, Wang M, Olivo S, DeAssis S, Gustafsson JA, Khan G & Hilakivi-Clarke L 2004 Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 25 741-748.
16. Carter TH, Liu K, Ralph W Jr, Chen D, Qi M, Fan S, Yuan F, Rosen EM & Auborn KJ 2002 Diindolylmethane alters gene expression in human keratinocytes in vitro. Journal of Nutrition 132 3314-3324.
17. Collaborative Group on Hormonal Factors in Breast Cancer 1996 Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347 1713-1727.
18. Collaborative Group on Hormonal Factors in Breast Cancer 1997 Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 10 8411 women without breast cancer. Lancet 350 1047-1059.
19. Deng CX 2002 Tumor formation in Brca1 conditional mutant mice. Environmental Molecular Mutagenesis 39 171-177.
20. de Villiers EM 2003 Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. International Journal of Cancer 103 705-758.
21. Easton DF, Ford D & Bishop DT 1995 Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. American Journal of Human Genetics 56 265-271.
22. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, Longy M, Guinebretiere JM, Sauvan R, Noguchi T, Birnbaum D & Sobol H 1998 Mutations at BRCA1 the medullary breast carcinoma revisited. Cancer Research 58 1588-1592.
23. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ & Arbeit JM 2000 Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Research 60 1267-1275.
24. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB & Herman JG 2000 Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. Journal of the National Cancer Institute 92 564-569.
25. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID & Rosen EM 1998 BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16 3069-3082.
26. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID & Rosen EM 1999 BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284 1354-1356.
27. Fan S, Meng Q, Gao B, Grossman J, Yadegari M, Goldberg ID & Rosen EM 2000 Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines. Cancer Research 60 5635-5639.
28. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG & Rosen EM 2001a Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20 77-87.
29. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID & Rosen EM 2001b Mutant BRCA1 genes antagonize phenotype of wild type BRCA1. Oncogene 20 8215-8235.
30. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG & Rosen EM 2002 p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Research 62 141-151.
31. Ferro P, Catalano MG, Dell'Eva R, Fortunati N & Pfeffer U 2002 The androgen receptor CAG repeat: a modifier of carcinogenesis? Molecular and Cellular Endocrinology 193 109-120.
32. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L & Wolmark N 1998 Tamoxifen for prevention of breast cancer Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 1371-1388.
33. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M & Akslen LA 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute 95 1482-1485.
34. Gowen LC, Johnson BL, Latour AM, Sulik KK & Koller BH 1996 Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nature Genetics 12 191-194.
35. Grabrick DM, Hartmann LM, Cerhan GR, Vierkant RA, Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson KE, Pankratz VS & Sellers TA 2000 Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. Journal of the American Medical Association 284 1791-1798.
36. Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstrale KK, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL & Olopade OI 2004 MYC is amplified in BRCA1-associated breast cancers. Clinical Cancer Research 10 499-507.
37. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J & Mak TW 1996 The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85 1009-1023.
38. Hakem R, de la Pompa JL, Elia A, Potter J & Mak TW 1997 Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nature Genetics 16 298-302.
39. Hall JM & McDonnell DP 1999 The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 5566-5578.
40. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA & Struewing JP 2002 Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers effects of reproductive history. Epidemiology 13 255-261.
41. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H & Ohta T 2001 The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. Journal of Biological Chemistry 276 14537-14540.
42. Heimdal K, Skovlund E & Moller P 2002 Oral contraceptives and risk of familial breast cancer. Cancer Detection and Prevention 26 23-27.
43. Henderson BE & Feigelson HS 2000 Hormonal carcinogenesis. Carcinogenesis 21 427-433.
44. Holmes MD & Willett WC 2004 Does diet affect breast cancer risk? Breast Cancer Research 6 170-178.
45. Jeffy BD, Chirnomas RB, Chen EJ, Gudas JM & Romagnolo DF 2002 Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: requirements for metabolism of benzo[a]pyrene to 7r,8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Cancer Research 62 113-121.
46. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS & Narod SA 1999 Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354 1846-1850.
47. Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P & Narod SA 2004 Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 96 1094-1098.
48. Jisa E & Jungbauer A 2003 Kinetic analysis of estrogen receptor homo- and heterodimerization in vitro. Journal of Steroid Biochemistry and Molecular Biology 84 141-148.
49. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V & Olsson H 1997 Tumour biological features of BRCA1-induced breast and ovarian cancer. European Journal of Cancer 33 362-371.
50. Jones LP, Li M, Halama ED, Ma Y, Lubet R, Grubbs CJ, Deng C-X, Rosen EM & Furth PA 2005 Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation related breast cancer. Oncogene, 24 3554-3562.
51. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K & Offit K 2002 Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine 346 1609-1615.
52. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J & Borg A 2000 MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Research 60 5323-5328.
53. Kawai H, Li H, Chun P, Avraham S & Avraham HK 2002 Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21 7730-7739.
54. Kelly MJ & Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. Trends in Endocrinology and Metabolism 12 152-156.
55. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B; National Surgical Adjuvant Breast and Bowel Project 2001 Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. Journal of the American Medical Association 286 2251-2256.
56. King TA, Gemignani ML, Li W, Giri DD, Panageas KS, Bogomolniy F, Arroyo C, Olvera N, Robson ME, Offit K, Borgen PI & Boyd J 2004 Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Research 64 5051-5053.
57. Kubista M, Rosner M, Kubista E, Bernaschek G & Hengstschlager M 2002 Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene 21 4747-4756.
58. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B & Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 4252-6263.
59. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF et al. 1998 Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. Journal of the National Cancer Institute 90 1138-1145.
60. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L & Easton DF 2002 The pathology of familial breast cancer predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. Journal of Clinical Oncology 20 2310-2318.
61. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA & Leder P 1995 Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes and Development 9 2712-2722.
62. Li S, Hursting SD, Davis BJ, McLachlan JA & Barrett JC 2003 Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Annals of the New York Academy of Science 983 161-169.
63. Liede A, Karlan BY & Narod SA 2004 Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. Journal of Clinical Oncology 22 735-742.
64. Liu CY, Flesken-Nikitin A, Li S, Zeng Y & Lee WH 1996 Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes and Development 10 1835-1843.
65. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber B, Tung N, Horsman D, Isaacs C, Monteiro AN, Sun P & Narod SA 2004 Cancer variation associated with the position of the mutation in the BRCA2 gene. Familial Cancer 3 1-10.
66. Ma YX, Tomita Y, Fan S, Wu K, Tong Y, Zhao Z, Song L-N, Goldberg ID & Rosen EM 2005 Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 24 1831-1846.
67. McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, John EM, West DW & Whittemore AS 2004 Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. American Journal of Epidemiology 160 613-618.
68. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA & Lynch HT 1996 Hereditary breast cancer pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77 697-709.
69. Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA & Iglehart JD 1997 BRCA1 is not directly responsive to estrogen. Oncogene 14 115-121.
70. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL & Chodosh LA 1995 The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genetics 11 17-26.
71. Meng Q, Yuan F, Goldberg ID, Rosen EM, Auborn K & Fan S 2000a Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. Journal of Nutrition 130 2927-2931.
72. Meng Q, Qi M, Chen DZ, Yuan R, Goldberg ID, Rosen EM, Auborn K & Fan S 2000b Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. Journal of Molecular Medicine 78 155-165.
73. Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE, Collins FS et al. 1995 Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clinical Cancer Research 1 539-544.
74. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD & Narod SA 2004 Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology 22 2328-2335.
75. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. 1994 A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 66-71.
76. Monteiro AN, August A & Hanafusa H 1996 Evidence for a transcription activation function of BRCA1 C-terminal region. PNAS 93 13595-13599.
77. Mosselman S, Polman J & Dijkema R 1996 ER-beta: identification and characterization of a novel human estrogen receptor. Federation of European Biochemical Societies Letters 392 49-53.
78. Narod SA 2001 Hormonal prevention of hereditary breast cancer. Annals of the New York Academy of Sciences 952 36-43. Review.
79. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group 2000 Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers a case-control study. Lancet 356 1876-1881.
80. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jerastrom H, Sun P & Brunet JS 2002 Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 94 1773-1779.
81. Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J & Crook T 1998 Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. European Journal of Cancer 34 1683-1686.
82. Ozcelik H, To MD, Couture J, Bull SB & Andrulis IL 1998 Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. International Journal of Cancer 77 1-6.
83. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sanchez L, Rivas C & Benitez J 2004 Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clinical Cancer Research 9 3606-3614.
84. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF & Coetzee GA 2000 Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Research 60 5946-5949.
85. Pettersson K, Delaunay F & Gustafsson JA 2000 Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 19 4970-4978.
86. Phillips KW, Goldsworthy SM, Bennett LM, Brownlee HA, Wiseman RW & Davis BJ 1997 Brca1 is expressed independently of hormonal stimulation in the mouse ovary. Laboratory Investigation 76 419-425.
87. Phillips KA, Andrulis IL & Goodwin PJ 1999 Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2 are they prognostically different? Journal of Clinical Oncology 17 3653-3663.
88. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA & Carlquist M 1999 Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. European Molecular Biology Organization Journal 18 4608-4618.
89. Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL & O'Malley FP 2002 HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 95 2068-2075.
90. Rajan JV, Wang M, Marquis ST & Chodosh LA 1996 Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammalian epithelial cells. PNAS 93 3078-3083.
91. Rajan JV, Marquis ST, Gardner HP & Chodosh LD 1997 Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Developmental Biology 184 385-401.
92. Rattenborg T, Gjermandsen I & Bonefeld-Jorgensen EC 2002 Inhibition of E2-induced expression of BRCA1 by persistent organochlorines. Breast Cancer Research 4 R12.
93. Razandi M, Pedram A, Rosen EM & Levin ER 2004 BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Molecular and Cellular Biology 24 5900-5913.
94. Rebbeck TR 2000 Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology 2000 18 (Suppl 21) 100-103.
95. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, Weber BL & Brown M 2001 Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Research 61 5420-5424.
96. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group 2002 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine 346 1616-1622.
97. Rice JC, Massey-Brown KS & Futscher BW 1998 Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17 1807-1812.
98. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ & Bernard-Gallon DJ 1999 Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. International Journal of Cancer 80 823-826.
99. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K & Foulkes WD 2004 A combined analysis of outcome following breast cancer differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research 6 R8-R17.
100. Rodriguez JA & Henderson BR 2000 Identification of a functional nuclear export sequence in BRCA1. Journal of Biological Chemistry 275 38589-38596.
101. Rosen EM, Fan S, Pestell RG & Goldberg ID 2003 BRCA1 gene in breast cancer. Journal of Cellular Physiology 196 19-41.
102. Ruffner H, Joazeiro CA, Hemmati D, Hunter T & Verma IM 2001 Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. PNAS 98 5134-5139.
103. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L & Hoover R 2000 Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Journal of the American Medical Association 283 485-491.
104. Shertzer HG & Senft AP 2000 The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metabolism and Drug Interactions 17 159-188.
105. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL & Botstein D 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100 8418-8423.
106. Staff S, Isola J & Tanner M 2003 Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Research 63 4978-4983.
107. Streuwing J, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC & Tucker MA 1997 The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 336 1401-1408.
108. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE et al. 1996 The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genetics 12 333-337.
109. Taylor J, Lymboura M, Pace PE, A'hern RP, Desai AJ, Shousha S, Coombes RC & Ali S 1998 An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. International Journal of Cancer 79 334-342.
110. Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T, Yao J, Farid LM, Couch FJ, Wilson RB & Weber BL 1997 Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Molecular and Cellular Biology 17 444-452.
111. The Women's Health Initiative Steering Committee 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. Journal of the American Medical Association 291 1701-1712.
112. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B & Polakis P 1997 Induction of phosphorylation of BRCA1 during the cell cycle and after DNA damage. Cell Growth and Differentiation 8 801-809.
113. Thompson D, Easton DF & Breast Cancer Linkage Consortium 2002 Cancer Incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute 94 1358-1365.
114. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A & Kallioniemi OP 1997 Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Research 57 1222-1227.
115. Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A & Bernstein L 1997 Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Research 57 3678-3681.
116. Vaziri SA, Tubbs RR, Darlington G & Casey G 2001 Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Molecular Pathology 54 259-263.
117. Venkitaraman AR 2002 Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 171-182.
118. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ & Klijn JG 1998 Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351 316-321.
119. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS & Narod S 1999 Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Journal of the National Cancer Institute 91 1241-1247.
120. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, Deng CX & Ried T 2002 Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21 5097-5107.
121. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M & Gustafsson JA 2000 Estrogen receptor (ER) beta, a modulator of ER alpha in the uterus. PNAS 97 5936-5941.
122. Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, Daly M, Usinowicz MB, Garlinghouse-Jones K, Ponder BA, Buys S, Senie R, Andrulis I, John E, Hopper JL & Piver MS 2004 Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British Journal of Cancer 91 1911-1915.
123. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ & Slamon DJ 1999 Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature Genetics 21 236-240.
124. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C & Micklem G 1995 Identification of the breast cancer susceptibility gene BRCA2. Nature 378 789-792.
125. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. Journal of the American Medical Association 288 321-333.
126. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM & Baer R 1996 Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nature Genetics 14 430-440.
127. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T & Deng CX 1999a Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Molecular Cell 3 389-395.
128. Xu X, Wagner K-U, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A & Deng C-X 1999b Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics 22 37-43.
129. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY & Chang C 2000 Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. PNAS 97 11256-11261.
130. Zheng L, Annab LA, Afshari CA, Lee WH & Boyer TG 2001 BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. PNAS 98 9587-9592.